US Patent

US9481663 — Crystalline forms of an androgen receptor modulator

Method of Use · Assigned to Memorial Sloan Kettering Cancer Center · Expires 2033-06-04 · 7y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects crystalline forms of the androgen receptor modulator used in pharmaceutical compositions for treating diseases associated with androgen receptor activity.

USPTO Abstract

Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2624 — Erleada
U-2624 — Erleada

Patent Metadata

Patent number
US9481663
Jurisdiction
US
Classification
Method of Use
Expires
2033-06-04
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Memorial Sloan Kettering Cancer Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.